Gadolinium encephalopathy in a patient with renal failure

Neurology

Volumn 64, Issue 7, 2005, Pages 1276-1278

  Maramattom, Boby Varkey ^a   Manno, Edward M ^a   Wijdicks, Eelco F M ^a   Lindell, Edward P ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CREATININE; GADOLINIUM; MULTIVITAMIN; THIAMINE;

ADULT; ARTICLE; BRAIN DISEASE; CASE REPORT; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID EXAMINATION; CLINICAL FEATURE; CREATININE BLOOD LEVEL; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; HUMAN CELL; HYPERTENSIVE CRISIS; IMAGE ANALYSIS; KIDNEY FAILURE; MENTAL HEALTH; NEUROLOGIC EXAMINATION; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; WHITE MATTER;

EID: 16844366654     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000156805.45547.6E     Document Type: Article

References (9)

1. Arsenault TM, King BF, Marsh JW, Jr., et al. Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: retrospective analysis of an initial experience. Mayo Clin Proc 1996;71:1150-1154.
2. Sharp S, Stone J, Beach R. Contrast agent neurotoxicity presenting as subarachnoid hemorrhage. Neurology 1999;52:1503-1505.
3. Taoka T, Yuh WT, White ML, Quets JP, Maley JE, Ueda T. Sulcal hyperintensity on fluid-attenuated inversion recovery mr images in patients without apparent cerebrospinal fluid abnormality. AJR Am J Roentgenol 2001;176:519-524.
4. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991;26:975-979.
5. Ray DE, Cavanagh JB, Nolan CC, Williams SC. Neurotoxic effects of gadolinium pentetate dimeglumine: behavioral disturbance and morphology after intracerebroventricular injection in rats. AJNR Am J Neuroradiol 1996;17:365-373.
6. Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging 1999;10:477-484.
7. Bozzao A, Floris R, Fasoli F, Fantozzi LM, Colonnese C, Simonetti G. Cerebrospinal fluid changes after intravenous injection of gadolinium chelate: assessment by FLAIR MR imaging. Eur Radiol 2003;13:592-597.
8. Rai AT, Hogg JP. Persistence of gadolinium in CSF: a diagnostic pitfall in patients with end-stage renal disease. AJNR Am J Neuroradiol 2001;22:1357-1361.
9. Kanamalla US, Boyko OB. Gadolinium diffusion into orbital vitreous and aqueous humor, perivascular space, and ventricles in patients with chronic renal disease. AJR Am J Roentgenol 2002;179:1350-1352.